title: Fractional CO2 laser in the treatment of facial scars in children.
abstract: Facial scars in children have a profound psychosocial impact and require early and aggressive treatment. In this age group in particular, however, attention must be placed on the methodology so as not to trigger additional trauma-whether physical or emotional-as a sequela to the treatment. We assess the safety and efficacy of fractional CO2 in a prospective study of pediatric facial scars from various etiologies. Twenty four children, age 2-16 years, underwent fractional CO2 laser resurfacing. Recovery, clinical response, and adverse events were monitored at 3 days, 1 week, 1 month, 2 months, and 6 months. Photographs taken before treatment and 2 months after final treatment were independently evaluated and scored by two physicians. All patients tolerated treatment well, with minimal erythema an edema. The clinical improvement was scored as excellent in 14 patients (58%), good in 7 (29%), and fair in 3 (13%). No cases were graded as poor or worse. No adverse events were noted. The study supports the use of fractional CO2 resurfacing of pediatric facial scars as well tolerated and effective. Given the particularly rapid healing and clinical improvement of pediatric skin, fractional CO2 treatment should be offered early to mitigate both the physical and psychosocial stigmata of scars as early as possible.
authors.affiliation: Department of Dermatology, Rabin Medical Center, Golda Campus, Petach Tikva, 49372, Israel, alapidot@netvision.net.il.
authors.forename: Moshe
authors.initials: M
authors.lastname: Lapidoth
authors.forename: Shlomit
authors.initials: S
authors.lastname: Halachmi
authors.forename: Sarit
authors.initials: S
authors.lastname: Cohen
authors.forename: Dan Ben
authors.initials: DB
authors.lastname: Amitai
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002921:Cicatrix / Q000473:pathology / Q000532:radiotherapy*; D004890:Erythema / Q000209:etiology; D005145:Face / Q000473:pathology; D006801:Humans; D054020:Lasers, Gas / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome